| CAS NO: | 273404-37-8 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Molecular Weight (MW) | 508.99 |
|---|---|
| Formula | C24H33ClN4O6 |
| CAS No. | 273404-37-8 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL warming (196.46 mM) |
| Water:<1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: 100 mg/mL warming (196.46 mM) | |
| Other info | Solubility (In vivo): 2% DMSO+30% PEG 300+ddH2O: 5 mg/mL Synonym: VX 765, VX765, VX-765, Belnacasan Chemical Name: (S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-N-((2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)pyrrolidine-2-carboxamide SMILES Code: O=C([C@H]1N(C([C@@H](NC(C2=CC=C(N)C(Cl)=C2)=O)C(C)(C)C)=O)CCC1)N[C@@H](C3)[C@H](OCC)OC3=O |
| General | In a CIA mouse model, VX-765 significantly reduced the inflammation scores in a dose-dependent manner. In addition, 100 mg/kg VX-765 was as efficacious as 5 mg/kg Prednisolone. |
|---|---|
| Animal model | Collagen-induced arthritis (CIA) mouse model |
| Formulation | VX-765 is dissolved in 25% Cremophor EL |
| Dosages | 10, 25, 50 or 100 mg/kg |
| Administration | p.o.; b.i.d.; for 24 days. |
| References | [1] Wannamaker W, et al. J Pharmacol Exp Ther. 2007, 321(2), 509-516. |
 Dose response of VX-765 in LPS-induced IL-1β production in vivo. Wannamaker W, et al. J Pharmacol Exp Ther. 2007 May;321(2):509-16. |  Effects of VX-765 on ear swelling induced by oxazolone.J Pharmacol Exp Ther. 2007 May;321(2):509-16. |  |
 |
m.cnreagent.com